Please assess the completion status of the following clinical trial:

Trial Title: Investigation of the Effect of Nintedanib on the Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Patients With Non-small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* Female patients 18 years or older at screening~* Female patient is postmenopausal or surgically sterilised~* Patient with locally advanced, metastatic or locally recurrent non-small cell lung cancer with histology of adenocarcinoma~* Nintedanib (Vargatef®) is planned to be prescribed in accordance with the marketing authorisation (SmPC)~* Signed and dated written informed consent in accordance with Good Clinical Practice (GCP) and local legislation prior to admission to the trial~Exclusion criteria:~* Any contraindication to nintedanib (Vargatef®), ethinylestradiol or levonorgestrel (Microgynon®), as specified in the respective labels~* Use of hormone containing contraceptives (including vaginal and intrauterine devices and including hormone replacement therapy) within 30 days prior to first administration of Microgynon®~* Systemic use of drugs known to induce (e.g. rifampicin, St. John's Wort, carbamazepine) or to inhibit (e.g. azole antimycotics, macrolides) CYP3A4 within 7 days prior to first trial drug administration until last pharmacokinetic(PK)-sampling in the trial. Exception: allowed is the intake of corticosteroids as docetaxel (pre)medication~* History of major thrombotic or clinically relevant major bleeding event in the past 6 months~* Persistence of clinically relevant therapy related toxicities (i.e. \> Common Terminology Criteria for Adverse Events \[CTCAE\] grade 2) from previous chemotherapy and/or radiotherapy~* Treatment with other investigational drugs or treatment in another clinical trial within the past four weeks before start of therapy or concomitantly with this trial~* Gastrointestinal disorders or abnormalities that would interfere with absorption of the trial drugs~* Major surgery (major according to the investigator's assessment) performed within 4 weeks prior to first treatment within the trial and without complete wound healing~* Patients who must or wish to continue the intake of restricted medications or any drug considered likely to interfere with the safe conduct of the trial~* Patients unable to comply with the protocol~* Previous enrolment in this trial

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- All Patients (Type: EXPERIMENTAL): Microgynon alone in Period 1 then with Nintedanib in Period 2

Based on this trial design, predict the completion outcome and termination type (if applicable).